

Increased Glucose Uptake and Insulin Binding Activity of *Nerium Oleander* in Hepatocytes and Adipocytes ^[1]

Nuray YAZIHAN *  Ahmet Levent BAS ** Ezgi ERMIS ***
Sule DEMIRCI **** Kamil UNEY **

[1] *This research was granted by The Scientific and Technological Research Council of Turkey (TUBITAK, Project No: 107 O 222)*

* Department of Pathophysiology, Molecular Biology R&D Unit, Faculty of Medicine, Ankara University, TR-06100 Ankara - TURKEY

** Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Selcuk University, TR-42003 Konya - TURKEY

*** Molecular Biology R&D Unit, Faculty of Medicine, Ankara University, TR-06100 Ankara - TURKEY

**** Department of Physiology, Faculty of Veterinary Medicine, Mehmet Akif Ersoy University, TR-15030 Burdur - TURKEY

Makale Kodu (Article Code): KVFD-2012-7044

Summary

Type 2 diabetes mellitus (DM) affects a large population worldwide. DM is often considered as a syndrome of disordered glucose metabolism. Current conventional drug therapies for DM are usually insufficient and medicinal herbs with antihyperglycemic activities are increasingly sought by diabetic patients and health care professionals. *Nerium Oleander* (N.O.) is known to be effective in lowering of postprandial blood glucose in DM patients as a folk remedy. In this study we aimed to evaluate effect of N.O. distillate in glucose uptake activity of hepatocytes and adipocytes. The human hepatoma cells Hep3B and mouse adipocyte 3T3-L1 cells were cultured. Depending on the groups, different concentrations insulin (1, 10, 20 IU/ml) and N.O. (0.1, 1, 10, 50 µg/ml) were added to medium for 48 h. Cellular toxicity and proliferation were evaluated by LDH secretion levels and MTT test. A metabolizable fluorescent derivative of glucose, 2-NBDG and FITC-insulin were used for glucose uptake and insulin binding activity. Insulin increased cellular proliferation and decreased LDH leakage and apoptosis in both cell types. Lower dosages of N.O. has no significant effect on apoptosis and cell number while at the highest dosages minimal cytotoxicity was seen mainly in adipocytes. Main effect of N.O. treatment was increased glucose uptake in Hep3B and 3T3-L1 cells ($P < 0.001$). Our results showed that N.O. may be offered as new approaches to treatment of type 2 diabetes by modulating cellular glucose uptake.

Keywords: *Nerium oleander, Hepatocytes, Adipocytes, Glucose uptake, Insulin binding, Type II diabetes mellitus*

Nerium Oleander'in Hepatositler ve Adipositlerde İnsulin Bağlanma ve Glukoz Alımını Arttırıcı Etkisi

Özet

Tip 2 diabet glukoz metabolizmasının bozukluğu şeklinde tanımlanan tüm dünyada oldukça yaygın bir hastalıktır. Mevcut tedavi yöntemleri yeterli gelmemekte, hastaların antihiperglisemik etkiye sahip tıbbi bitkilerle tedaviye ilgisi artmaktadır. *Nerium Oleander* (N.O.) diabetik hastalarda postprandial glukoz düzeyini düşürmek amacıyla yerel olarak kullanılmaktadır. Bu çalışmada N.O. ekstraktının karaciğer ve adiposit hücrelerinde glukoz alımına ve insülin bağlanmasına etkilerinin belirlenmesi amaçlanmıştır. Farklı dozlarda insülin (1-20 IU/ml) ve N.O. (0.1-50 µg/ml) 48 h uygulamasının İnsan hepatosit Hep3B ve fare adipositleri 3T3-L1 hücre dizileri üzerindeki etkileri değerlendirilmiştir. Bu amaçla hücre toksitesi LDH sekresyonu, hücre çoğalması MTT yöntemi ve hücre içine glukoz alımı/insülin bağlanması florimetrik yöntemle 2-NBDG ve FITC-insülin kullanılarak ölçülmüştür. İnsülin uygulaması her iki hücrede de proliferasyonu arttırmış, LDH sekresyonunu azaltmıştır. Düşük dozlarda N.O. uygulamasının hücre sayısına etkisi görülmezken kullanılan üst dozlarda adipositlerde sitotoksik etkisi gözlenmiştir. N.O. nun adiposit ve hepatositlerde hücre içine glukoz alımını anlamlı arttırdığı gözlenmiştir ($P < 0.001$). Çalışmamız sonuçları N.O. ekstraktının tip 2 diabette özellikle insülin ve glukoz kullanımını düzenleyici etkisi nedeniyle önemli yeni bir tedavi alternatifini olabileceğini göstermiştir.

Anahtar sözcükler: *Nerium oleander, Hepatositler, Adipositler, Glukoz alımı, İnsulin bağlanması, Tip II Diabetes mellitus*



İletişim (Correspondence)



+90 312 3103010/372



nurayyazihan@yahoo.com

INTRODUCTION

Type 2 diabetes mellitus (DM) affects a large population worldwide¹. There have been many attempts to develop the safe and effective methods of curing diabetes. Although very intensive research is being conducted in this field, current protocols still have only limited applications. The general consensus on treatment of type 2 diabetes is that lifestyle management is at the forefront of therapy options. In addition to exercise, weight control, and medical nutrition therapy, oral glucose-lowering drugs and injections of insulin are the conventional therapies. Alternative treatments for diabetes have become increasingly popular the last several years, including medicinal herbs, nutritional supplementation and acupuncture. Plant derivatives with purported hypoglycemic properties have been used in folk medicine and traditional healing systems around the world. Approximately 1200 plants are used worldwide for the empirical treatment of DM. However, only about 350 of them are documented to present hypoglycemic activity although only a small number of these have received scientific and medical evaluation to assess their efficacy^{2,3}. The World Health Organization Expert Committee on diabetes has recommended that traditional medicinal herbs be further investigated^{1,4}.

Some of the most common plants used traditionally for treatment of diabetes are *Pterocarpus marsupium*⁵, *Bitter Melon*⁶, *Gymnema Sylvestre*⁷, *Asian Ginseng*⁸, *Soybean*⁹ and *Cinnamon*¹⁰.

Nerium oleander (N.O.) is a member of Apocynaceae familia and grown in Mediterranean region. *Nerium indicum* is known to be effective in lowering of postprandial blood glucose in DM patients and both *oleander* and *indicum* subforms are now used as a folk remedy for type II diabetes in some regions of Mediterranean region and Asia¹¹. The hot water extract of the leaves of N.O. has been used as a remedy against Type II DM with subjective success but without corroborating laboratory data. First report related to the hypoglycemic activity of the plant is given by Bellakhdar et al.¹² and then reported by other authors^{13,14}.

DM is a complex group of metabolic disorders including hyperglycemia and impaired insulin secretion and/or insulin response. Current theories of DM include a defect in insulin-mediated glucose uptake in muscle and adipocytes, a dysfunction of the pancreatic β -cells, an impaired insulin action in liver and decreased peripheral (muscle) glucose utilization. Changes in glucose clearance, an index of efficiency of glucose removal from the circulation, by itself do not affect plasma glucose concentrations independent of changes in rates of glucose entry and exit^{15,16}. In this study we aimed to evaluate *in vitro* direct effect of N.O. in hepatocyte and adipocyte cells especially with the aspect of glucose uptake metabolism and cellular proliferation.

MATERIAL and METHODS

Cell lines, Chemicals and Materials

Human hepatoma cell line Hep3B and mouse preadipocyte cells 3T3-L1 were obtained from the American Type Culture Collection (ATCC). Hep3B cells were cultured in Roswell Park Memorial Institute-1640 (RPMI, PAA, Austria) and 3T3-L1 cells in Dubellco's Modified Eagles Medium (DMEM, PAA, Austria), supplemented with fetal calf serum (FCS), (PAA, Austria), L-glutamine, streptomycin and penicillin (Sigma, MO, USA). Insulin (Sigma, MO, USA) was dissolved in water, sterilized by 0.22 μ m pore size cellulose acetate membrane filters, and added to cultures at the indicated time and concentrations. Cell counts were tested by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma, MO, USA). Lactate Dehydrogenase (LDH) and glucose levels were measured with commercial kits using an automatic multi-analyzer (Roche; P800).

Obtaining Lyophilized *Nerium oleander*

Nerium oleander plant was collected among new shoots in March-September period from Mediterranean region of Turkey. After washing collected plant, fresh shoots were chopped, and adequate distilled water added. The mixture was heated in heat resistant container. After liquid started to evaporate, container lid was covered and vapor was separated to other clean glass container by causing it to come to contact with a surface cooled with cold water. N.O. distillate was lyophilized in small glass bottle (20 ml) by using lyophilizator. N.O. lyophilized distillate was dissolved in according to dosage in saline solution then sterilized by 0.22 μ m pore size cellulose acetate membrane filters, and added to cultures at the indicated time and concentrations.

Cell Culture and Experimental Protocol

The human hepatoma cell line Hep3B was cultured in RPMI-1640 medium and 3T3-L1 cells in DMEM, supplemented with 10% v/v fetal calf serum, 2 mmol/L L-glutamine, streptomycin (100 mg/mL) and penicillin (100 IU/mL) in a humidified atmosphere containing 5% CO₂ at 37°C. One day before the experiments, cells were seeded on 96-well microtitre plates (Nunc, Denmark) at 2X10⁵ cells/mL.

Depending on the groups, different concentrations insulin (1, 10, 20 IU/ml) and N.O. (0.1, 1, 10, 50 μ g/ml) were added to medium for 48 h.

LDH levels were evaluated from control and treated cells at the 48th h. MTT was measured at the 2nd, 24th and 48th h. After supernatants were removed cell surface was washed with sterile phosphate buffered saline (PBS) and cells were harvested with lysis solution and caspase-3 levels of groups were measured from cell lysates. LDH measurement was done from both of the supernatant and cell lysates.

Evaluation of Cellular Proliferation or Death

MTT, a colorimetric assay based upon the ability of living cells to reduce MTT into formazan, was used for evaluation of the effects of dose and time dependent effects of glucose, insulin and N.O. on cellular death or proliferation (24th, 48th h). Cell number % was calculated as ratio of cell number of effected group vs control group 100 at the determined hours.

Biochemical Determination of Cell Death

Hep3B cells were plated in 96 multiwell cell culture plates as 3×10^5 cells/mL. LDH is normally present in the cytosol of hepatocytes. In response to cell damage LDH is released from the cells. Therefore, to determine cell death, we measured secreted and intracellular LDH levels and calculated % released LDH at the 48th h for each group. To do this, the medium was collected to measure enzyme activities. The adherent cells were lysed. Both medium and cell lysates were used for quantitative determination of LDH activity (IU/L) which was performed with an automatic multianalyzer (Roche, MN, USA) using commercial kit (Roche, MN, USA). Released enzyme fractions for each sample were calculated as the ratio of enzyme present in the medium vs the sum of the levels of same enzyme in the supernatant and in the cells.

Glucose Uptake and Insulin Binding Activity

A metabolizable fluorescent derivative of glucose, 2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)Amino)-2-Deoxyglucose (2-NBDG, Molecular Probes, Oregon, USA), was used. Following incubation at 37°C for 120 min with the dye, culture medium was removed and after washing the cells with Hanks' balanced salt solution (HBSS) fluorescence was measured in Spectromax M2 fluorescence microplate reader (Perkin-Elmer Corp. Norwalk, CT, USA) set at an excitation wavelength of 470 nm and an emission wavelength of 550 nm. To determine the effect of insulin or N.O. on glucose uptake, the cell suspension was dispensed in 96-well microtiter plates at 2500 cells/well (200 ml). After 24 h of incubation (37°C/ 5% CO₂), all culture medium was removed from each well and replaced with 100 ml of culture medium with different concentrations of insulin and and 100 ml of 300 µM 2-NBDG diluted in the same medium to give a final concentration of 150 µM /well. In this case, cells were incubated simultaneously

with both insulin/N.O. and 2-NBDG for 120 min, and then the plates were centrifuged, the culture medium was removed and the cells were washed once with HBSS. Fluorescence was measured as previously described and results of triplicate experiments expressed as 2-NBDG concentrations¹⁷.

Same procedure was repeated with 0.3 mM Fluorescein isothiocyanate (FITC) labeled Insulin. Fluorescence was measured at an excitation wavelength of 490 nm and an emission wavelength of 520 nm¹⁸.

Statistical Analysis

Results of the experiments were analyzed by One Way ANOVA, followed by a multiple comparison test using SPSS 13.0. $P < 0.05$ was accepted as statistically significant. Results were given as mean \pm SEM.

RESULTS

We characterized the concentration-dependent effect of N.O. and insulin on human hepatocyte cell line (Hep3B) and mouse adipocyte cell line (3T3-L1) as a function of time. N.O. treatment decreased adipocyte cell number ($P < 0.01$) whereas insulin increased ($P < 0.01$, Fig. 1). Minimal toxic effect is seen at the highest dose of N.O. ($P < 0.05$) in Hep3B cells (Fig. 2).

Insulin treatment decreased LDH leakage, higher doses of N.O. treatment increased LDH leakage ($P < 0.01$, Fig. 3).


Main effect of N.O. treatment was seen in glucose uptake to Hep3B and 3T3-L1 cells ($P < 0.001$, Fig. 4, 5) and this effect is more prominent in liver cells and significantly different from control and insulin treated cells ($P < 0.001$). N.O. treatment increased insulin binding capacity in both adipocytes and hepatocytes ($P < 0.001$, Fig. 6).

DISCUSSION

Both experimental and epidemiologic studies showed that insulin resistance is not key factor only in diabetes also in cardiovascular diseases¹⁹. Control of blood glucose levels is a function and coordination of different organ systems such as liver, pancreas, muscle and fat. These organs and tissues

Fig 1. Cell number was determined at 24th and 48th h in adipocyte cell line 3T3-L1. NO treatment caused significant cytotoxicity with dose and time dependent manner ($P < 0.01$). The effect is most prominent in N.O. 10 µg/ml dose and at 24th h ($P < 0.001$). Insulin treatment increased cell number at 48th h in all concentrations ($P < 0.01$). Data are presented as mean \pm SEM (n=6)

Şekil 1. Adiposit hücre dizisinde (3T3-L1) hücre proliferasyonunun 24 ve 48. saatlerde değerlendirilmesi. N.O. tedavisi doz ve zaman bağımlı olarak sitotoksik etki göstermiştir ($P < 0.01$). Bu etki NO 10 µg/ml dozda ve 24. saatte en belirgindir ($P < 0.001$). İnsulin tedavisi 48. saatte hücre proliferasyonunu tüm dozlarda arttırmıştır ($P < 0.01$). Sonuçlar ortalama \pm SEM olarak verilmiştir (n=6)






Fig 2. Cell number was determined at 24th and 48th h by the MTT assay. N.O. treatment has minimal cytotoxic effect in highest dosage in Hep3B cell line ($P<0.05$). Insulin treatment increased cell number in all concentrations ($P<0.001$). Data are presented as mean \pm SEM (n=6)

Şekil 2. Hepatosit hücre dizisinde 24 ve 48. saatlerde hücre sayımının MTT ile değerlendirilmesi. N.O. tedavisi en yüksek dozda hepatositlerde minimal toksik etki göstermiştir ($P<0.05$). İnsulin tedavisi tüm dozlarda proliferative etki göstermiştir ($P<0.001$). Sonuçlar ortalama \pm SEM olarak verilmiştir (n=6)

Fig 3. N.O. treatment increased LDH released to medium at 48th h. Starting from the 1 IU/mL dosage insulin treatment decreased LDH release from hepatocytes at the 24th and 48th h ($P<0.01$). Data are presented as mean \pm SEM

Şekil 3. N.O. tedavisi hepatositlerde LDH sekresyonunu 48. saatte artırmıştır. İnsulinin 1 IU/mL dozundan itibaren hepatositlerde LDH sekresyonunu 24 ve 48. saatlerde azaltmıştır ($P<0.01$). Sonuçlar ortalama \pm SEM olarak verilmiştir (n=6)





Fig 4. Basal and insulin-stimulated NBDG-glucose uptake in cultured human hepatocytes. N.O. treatment increased glucose uptake in hepatocytes compared to control and insulin treated cells ($P<0.001$). Data are presented as mean \pm SEM

Şekil 4. Hepatositlerde bazal ve insülinle uyarılmış NBDG-glukoz alımı. N.O. tedavisi hepatositlerde hücre içine glukoz alımını kontrole ve insülin göre belirgin arttırmıştır ($P<0.001$). Sonuçlar ortalama \pm SEM olarak verilmiştir (n=6)





Fig 5. Basal and insulin-stimulated NBDG-glucose uptake in cultured adipocytes N.O. treatment increased glucose uptake in adipocytes starting from lower dosages but most prominent at 10 μ g/ml dosage compared to control and insulin treated cells ($P<0.001$). Data are presented as mean \pm SEM

Şekil 5. Adipositlerde bazal ve insülinle uyarılmış glukoz alımı. N.O. tedavisi adipositlerde düşük dozlardan itibaren hücre içine glukoz alımını arttırmıştır, bu etki en belirgin 10 μ g/ml dozdadır ($P<0.001$). Sonuçlar ortalama \pm SEM olarak verilmiştir (n=6)



have major roles in the use and storage of nutrients in the form of glycogen and triglycerides. Type II DM is the most common disorder which is characterized by impaired insulin stimulated glucose uptake in muscle and adipose tissue ²⁰.

It is striking that peripheral glucose levels should be well

regulated by physiological control mechanisms, which, when deregulated, trigger early signs of the pathogenesis of obesity and diabetes, such as abnormal suppression of glucagon and loss of insulin secretion in the fed state and decreased peripheral tissue glucose uptake. These dysregulations become prominent before full impairment




Fig 6. Basal and N.O.-stimulated FITC-Insulin binding activity in cultured adipocytes and hepatocytes. N.O. treatment increased insulin binding in adipocytes and hepatocytes as dose dependent manner ($P < 0.001$). Data are presented as mean \pm SEM

Şekil 6. Hepatositlerde ve adipositlerde bazal ve N.O. ile uyarılmış insülin bağlanma kapasitesi. N.O. tedavisi adipositlerde ve hepatositlerde insülin bağlanmasını doz bağımlı olarak arttırmıştır ($P < 0.001$). Sonuçlar ortalama \pm SEM olarak verilmiştir (n=6)

of beta-cell secretion and insulin resistance appears, a characteristic of established type 2 DM^{20,21}. Also dysregulation of extrapancreatic glucose sensors, especially glucose uptake, may be early events in the pathogenesis of obesity and type 2 diabetes²¹. From the physiologic standpoint, activation of glucose transport and glycogen synthase is linked to the insulin-signaling mechanism in many systems. Glucose entry into the primary insulin target tissues (skeletal muscle, heart, adipose tissue, and liver) occurs by facilitated diffusion, mediated by a family of transport proteins. Glucose transporters (GLUT) mainly GLUT 1-4 mediates insulin stimulated glucose uptake by skeletal muscle, heart, and adipose tissues²¹. Adipocyte metabolism starts to take famous roles in recent studies. It is accepted now that altered adipocyte metabolism, fat storage and distribution is very important in the pathogenesis of glucose intolerance in Type 2 DM²². Chronically increased glucose and plasma free fatty acids FFA stimulates adipogenesis and further gluconeogenesis leading to hepatic/muscle insulin resistance. Dysfunctional fat cells produce excessive amounts of insulin resistance-inducing, inflammatory, and atherosclerotic-provoking cytokines and fail to secrete normal amounts of insulin-sensitizing adipocytokines. Fat cells start to proliferate and become enlarged and more insulin resistant. Different therapies are used to enhance adipocyte insulin sensitivity, reduce plasma FFA, and favorably influence the production of adipocytokines²³. Thiazolidinediones are insulin-sensitizing antidiabetic agents which are used in DM patients²⁴. Researchers are seeking new alternative treatments to decrease intracellular concentrations of triglyceride metabolites in muscle, liver, and β -cells, contributing to improvements in muscle/hepatic insulin sensitivity and pancreatic and liver function in type 2 diabetics.

Alternative therapies with anti-hyperglycemic effects are increasingly sought by patients with diabetes. This comes as no surprise since alternative treatments have been most widely used in chronic diseases, which may be only partially alleviated by conventional treatment. Herbal medications are the most commonly used alternative therapy for blood sugar control; however, their safety and efficacy need to be further evaluated by well-designed, controlled clinical studies. N.O. is well known toxic plant especially with its chemotherapeutic potential. Yassin and Mwafy²⁵ showed anti-lipidemic effect without toxicity at the dose Haeba et al.²⁶

determined with toxicological studies of N.O. leaflets. Similarly; Gayathri et al.²⁷ found that N.O. extract had an antilipidemic effect in high fat diet fed rats.

Hepatotoxicity of N.O. extract is tested by MTT, LDH leakage measurements in human hepatocytes and we did not find toxic effect or minimal toxicity is found with higher dosages. However, the action mechanism of N.O. is not known yet in the regulation of glucose metabolism. We found that N.O. increases glucose uptake in both cell type, especially in liver cells which is more important for glucose retrieval from blood. Our data suggest that N.O. acts through increase in insulin binding and may effect glucose utilization in adipocytes, and hepatocytes.

In summary, we conclude that N.O. is a bioactive component in hepatocytes and adipocytes and able to regulate glucose metabolism and insulin sensitivity in cells. Further investigations are required to evaluate the underlying mechanisms of benefit of N.O. treatment.

ACKNOWLEDGEMENTS

The authors declare that there is no conflict of interest that would prejudice the impartiality of this scientific work. Also the research results were applied to Turkish Patent Institute (Application No: 2009/00312) and Patent Cooperation Treaty (Application No: PCT/TR2009/000013).

REFERENCES

- WHO:** Library Cataloguing-in-publication data, Diabetes Action Now. An initiative of the World Health Organization and the International Diabetes Federation 2004.
- Alarcon-Aguilar FJ, Roman-Ramos R, Flores-Saenz JL, Aguirre-Garcia F:** Investigation on the hypoglycaemic effects of extracts of four Mexican medicinal plants in normal and alloxan-diabetic mice. *Phytother Res*, 16 (4): 383-386, 2002.
- Modak M, Dixit P, Londhe J, Ghaskadbi S, Paul A Devasagayam T:** Indian herbs and herbal drugs used for the treatment of diabetes. *J Clin Biochem Nutr*, 40 (3): 163-173, 2007.
- Dey L, Attele AS, Yuan CS:** Alternative therapies for type 2 diabetes. *Altern Med Rev*, 7 (1): 45-58, 2002.
- Dhanabal SP, Kokate CK, Ramanathan M, Kumar EP, Suresh B:** Hypoglycaemic activity of *Pterocarpus marsupium* Roxb. *Phytother Res*, 20 (1): 4-8, 2006.
- Leung L, Birtwhistle R, Kotecha J, Hannah S, Cuthbertson S:** Anti-diabetic and hypoglycaemic effects of *Momordica charantia* (bitter melon):

A mini review. *Br J Nutr*, 102 (12): 1703-1708, 2009.

7. Srivastava Y, Nigam SK, Bhatt HV, Verma Y, Prem AS: Hypoglycemic and life-prolonging properties of *Gymnema sylvestre* leaf extract in diabetic rats. *Isr J Med Sci*, 21 (6): 540-542, 1985.

8. Banz WJ, Iqbal MJ, Bollaert M, Chickris N, James B, Higginbotham DA, Peterson R, Murphy L: Ginseng modifies the diabetic phenotype and genes associated with diabetes in the male ZDF rat. *Phytomedicine*, 14 (10): 681-689, 2009.

9. Kwon DY, Daily JW 3rd, Kim HJ, Park S: Antidiabetic effects of fermented soybean products on type 2 diabetes. *Nutr Res*, 30 (1): 1-13, 2010.

10. Jitomir J, Willoughby DS: Cassia cinnamon for the attenuation of glucose intolerance and insulin resistance resulting from sleep loss. *J Med Food*, 12 (3): 467-472, 2009.

11. Ishikawa A, Yamashita H, Hiemori M, Inagaki E, Kimoto M, Okamoto M, Tsuji H, Memon AN, Mohammadio A, Natori Y: Characterization of inhibitors of postprandial hyperglycemia from the leaves of *Nerium indicum*. *J Nutr Sci Vitaminol (Tokyo)*, 53 (2): 166-173, 2007.

12. Bellakhdar J, Claisse R, Fleurentin J, Younos C: Repertory of standard herbal drugs in the Moroccan pharmacopoeia. *J Ethnopharmacol*, 35, 123-143, 1991.

13. Bnouham M, Mekhfi H, Legssyer A, Ziyat A: Ethnopharmacology Forum Medicinal plants used in the treatment of diabetes in Morocco. *Int J Diabetes & Metabolism*, 10, 33-50, 2002.

14. Tahraoui A, El-Hilaly J, Israili ZH, Lyoussi B: Ethnopharmacological survey of plants used in the traditional treatment of hypertension and diabetes in south-eastern Morocco (Errachidia province). *J Ethnopharmacol*, 110 (1): 105-117, 2007.

15. Marshall S, Garvey WT, Traxinger RR: New insights into the metabolic regulation of insulin action and insulin resistance: Role of glucose and amino acids. *FASEB J*, 5 (15): 3031-3036, 1991.

16. Khan AH, Pessin JE: Insulin regulation of glucose uptake: a complex interplay of intracellular signalling pathways. *Diabetologia*, 45 (11): 1475-1483, 2002.

17. Leira F, Louzao MC, Vieites JM, Botana LM, Vieytes MR: Fluorescent

microplate cell assay to measure uptake and metabolism of glucose in normal human lung fibroblasts. *Toxicol In Vitro*, 16 (3): 267-273, 2002.

18. Gok E Olgaz S: Binding of Fluorescein Isothiocyanate to Insulin: A fluorimetric labeling study. *J Fluorescence*, 14 (2): 203-206, 2004.

19. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr: International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. *Circulation*. 16, 1640-1645, 2010.

20. Thorens B: Glucose sensing and the pathogenesis of obesity and type 2 diabetes. *Int J Obes (Lond)*. 6 (Suppl): S62-S71, 2008.

21. Gould GW, Holman GD: The glucose transporter family: Structure, function and tissue-specific expression. *Biochem J*, 95 (Pt 2): 329-341, 1993.

22. De Ferranti S, Mozaffarian D: The perfect storm: Obesity, adipocyte dysfunction, and metabolic consequences. *Clin Chem*, 54 (6): 945-955, 2008.

23. Antuna-Puente B, Feve B, Fellahi S, Bastard JP: Adipokines: the missing link between insulin resistance and obesity. *Diabetes Metab*, 34 (1): 2-11, 2008.

24. Samuel VT, Petersen KF, Shulman GI: Lipid-induced insulin resistance: Unravelling the mechanism. *Lancet*, 375 (9733): 2267-2277, 2010.

25. Yassin MM, Mwafy SN: Protective potential of glimepiride and *Nerium oleander* extract on lipid profile, body growth rate, and renal function in streptozotocin-induced diabetic rats. *Turk J Biol*, 31, 95-102, 2007.

26. Haeba MH, Mohamed AI, Mehdi AW Nair GA: Toxicity of *Nerium oleander* leaf extract in mice. *J Environ Biol*, 23, 231-237, 2002.

27. Gayathri V, Ananthi S, Chandronitha C, Sangeetha MK, Vasanthi HR: Hypolipidemic potential of flowers of *Nerium oleander* in high fat diet-fed Sprague Dawley rats. *Nat Prod Res*, 25 (11): 1110-1114, 2011.